首页 正文

Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis

{{output}}
Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, commonly treated for Type 2 diabetes mellitus (T2DM), have demonstrated benefits in reducing cardiovascular and renal events. However, heart failure (HF) and chronic kidney... ...